3 results
The primary objective of this study is to determine the sensitivity of the marker bevacizumab-IRDye800CW using innovative NIR fluorescence endoscopy (visualizing with wide-field endoscopy, measuring with MDSFR/SFF spectroscopy and optionally…
Primary: To estimate the antitumor activity (assessed as overall response rate) of PDR001 as a single agent in patients with non-functional neuro-endocrine tumors (NET).Secondary: To estimate efficacy (duration of response) of PDR001. Safety and…
* Safety Run inTo determine the recommended regimen of PDR001 in combination with dabrafenib and trametinib for the randomized part (part 3)* Biomarker cohortTo evaluate changes in the immune microenvironment and biomarker modulations upon treatment…